What Is an Artificial Meniscus Replacement?

An artificial meniscus replacement is a synthetic or bio-engineered device implanted into the knee to restore the cushioning and load-distributing function of a damaged or removed meniscus. These devices range from porous scaffolds that encourage your body to grow new tissue into the implant, to solid prosthetics designed to mimic the shape and mechanical behavior of the original meniscus. The field sits at an interesting crossroads: partial scaffolds have accumulated decades of clinical data, a fully synthetic total replacement has entered clinical trials, and 3D-bioprinted menisci are being tested in laboratories. None of these options is yet as routine as a knee replacement, and the technology is evolving fast enough that what is available today looks quite different from what was available even five years ago.

Why Your Meniscus Matters So Much

The meniscus is a crescent-shaped wedge of tough, rubbery cartilage that sits between the thighbone and shinbone. Each knee has two: a medial meniscus on the inside and a lateral meniscus on the outside. Together, they absorb shock, spread the load of your body weight across a wider area of cartilage, and help stabilize the joint during movement. When the meniscus is intact, the forces passing through the knee are distributed relatively evenly. When part or all of it is removed, the remaining cartilage bears a much more concentrated load, and that accelerates wear.

For decades, the standard treatment for a badly torn meniscus was partial or total meniscectomy, meaning the surgeon trimmed away or removed the damaged tissue. Pain often improved in the short term, but the long-term picture is sobering. A meta-analysis of studies comparing meniscus repair to meniscectomy found that patients who had their meniscus removed were roughly twice as likely to develop advanced knee osteoarthritis and to eventually need a total knee replacement, compared with patients whose meniscus was repaired.¹ That gap is the core problem artificial meniscus replacements are trying to solve: once the meniscus is gone, nothing currently in wide clinical use can replace its mechanical function before the joint starts breaking down.

Partial Meniscal Scaffolds

The most established artificial meniscus devices are not full replacements in the way a hip implant replaces a hip joint. They are scaffolds, porous structures sutured into the space left after a partial meniscectomy. The idea is that the scaffold provides a temporary framework, and your body gradually fills it with new fibrocartilage-like tissue while the scaffold itself breaks down or integrates. Two commercial scaffolds have accumulated the most clinical evidence: one based on collagen and one made from polyurethane.

Collagen Meniscus Implant

The collagen meniscus implant (often referred to by its original brand name CMI) was one of the first to reach clinical use. It is a resorbable scaffold made from purified collagen that supports tissue ingrowth. Early clinical studies confirmed that new fibrocartilage matrix formed within the scaffold as it was absorbed.² More recent work using three-dimensional volume analysis of the regenerated tissue has shown stable scaffold incorporation and measurable meniscal regeneration at twelve months after implantation.³ In systematic reviews, the CMI has shown a failure rate of about 6.5% over a mean follow-up of roughly eight years, which is relatively low for a biological scaffold device.⁴

Polyurethane Scaffold

The polyurethane scaffold, marketed as Actifit, works on a similar principle but uses a synthetic polymer rather than animal-derived collagen. Its porous structure is designed to allow tissue infiltration over time. At two-year follow-up, studies of Actifit used for lateral meniscus defects have reported significant improvements in pain and function scores.⁵ Longer-term data at a minimum of ten years tells a more detailed story: patients saw meaningful gains across multiple knee function scores, and pain scores roughly halved, but MRI showed that most scaffolds were partially extruded from their original position over time.⁶ The failure rate for Actifit in systematic reviews is about 18% over a mean follow-up of around five and a half years, higher than the CMI’s rate.⁴

Case reports have also described Actifit being used successfully in younger patients, including a skeletally immature adolescent who had a stable functional outcome five years after implantation.⁷ That is worth noting because younger patients face the longest window of time during which a meniscus-deficient knee can deteriorate, making them the population with the most to gain from a functional scaffold.

Total Synthetic Meniscus Replacement

Partial scaffolds require a remaining rim of native meniscus tissue to anchor to. If too much meniscus has been removed, scaffolds are not an option. That is where a true total replacement comes in, and the most advanced device in this category is the NUsurface implant. It is a free-floating, disc-shaped prosthetic made of flexible polycarbonate-urethane reinforced with ultra-high-molecular-weight polyethylene fibers. Its wedge-shaped geometry makes it self-centering in the joint: during movement, it naturally shifts to fill the space between the bones.⁸

The NUsurface is designed to replace the medial meniscus and is intended for patients who are still symptomatic after meniscectomy and have not responded to non-surgical treatment.⁹ Importantly, the device is not anchored with screws or sutures. Instead, it relies on having at least two millimeters of intact peripheral meniscal rim to keep it from dislocating.⁸ That requirement means the NUsurface is not suited for patients whose meniscus has been completely removed down to the capsule wall.

The clinical picture for the NUsurface is still maturing. Early data shows a failure rate of about 17% at twelve months, and there is a recognized pattern of high reoperation rates, though patients who retain the implant or receive an exchange do report improvements in knee pain and function.⁴ The device has been available in Europe and is under investigation in broader clinical trials, but as of the time of writing it does not have FDA clearance in the United States.¹⁰

How Synthetic Implants Compare to Donor Tissue

Artificial meniscus devices are not the only option for someone who has lost meniscal tissue. Meniscal allograft transplantation, where a donor meniscus from a cadaver is surgically implanted, has been performed since the 1980s and remains the most common form of meniscal replacement worldwide. The question patients reasonably ask is: which works better?

A large systematic review covering nearly 4,000 patients found that both approaches produced significant improvements across all clinical scores. The synthetic scaffold group actually showed greater improvements in several function measures, while the allograft group showed a larger reduction in pain scores.¹¹ At ten years, synthetic scaffolds had a higher survival rate, though mid-term survival was comparable. Scaffolds also had a lower complication rate.¹¹ A separate meta-analysis echoed this, finding that commercial synthetic products outperformed allografts on pain, function, and osteoarthritis outcome scores.¹²

These findings sound like a clear win for synthetic devices, but context matters. Allografts and scaffolds are generally used in different situations. A scaffold requires a peripheral rim of native tissue, while an allograft can replace the entire meniscus. That means the sickest knees, the ones with the least remaining tissue, tend to get allografts and start from a worse baseline. Some of the outcome gap may reflect that selection bias rather than a genuine superiority of the material. Allografts also require size-matched donor tissue, which introduces logistical challenges and waiting times that synthetics avoid.

Recovery After Implantation

Rehabilitation after meniscus replacement is substantially more conservative than recovery from a simple meniscectomy, where patients are often back to near-normal activity within weeks. After a scaffold or prosthetic implantation, the timeline stretches out to protect the new device while tissue integrates.

A review of rehabilitation protocols found that full weight-bearing is typically allowed after about six weeks on average, with complete consensus across protocols that patients should be fully weight-bearing by ten weeks. Full range of motion is restored around seven weeks, with agreement across all protocols that it should be achieved by nine weeks. A knee brace is generally worn for about eight weeks.¹³ All of those timelines are significantly longer than what is recommended after meniscus repair alone, let alone meniscectomy.

A 2024 EU-US consensus statement on meniscus rehabilitation emphasized that recovery after meniscus reconstruction should be guided by both time-based and criterion-based milestones, meaning you progress when you hit specific strength and function benchmarks, not just when the calendar says you can.¹⁴ The same guidance applies regardless of whether the procedure is on the medial or lateral side of the knee.

Who Is a Good Candidate

Not everyone with knee pain from a missing meniscus is a candidate for an artificial replacement. The field is still narrowing down exactly who benefits most, but some broad criteria have emerged from the available evidence.

For partial scaffolds like the CMI or Actifit, you typically need to have had a partial meniscectomy with some remaining rim of meniscal tissue to anchor the implant to. The knee should not already have advanced osteoarthritis, because a scaffold cannot reverse cartilage damage that has already occurred. It can only help slow further progression by restoring some load distribution. Patients need to have intact or reconstructed ligaments, since a scaffold in an unstable knee will not survive. Age is less of a strict cutoff than joint health; as the adolescent case report illustrates, younger patients can benefit if the indication is right.

For the NUsurface total replacement, the target patient is someone who remains symptomatic after medial meniscectomy, has failed conservative management, and still has at least a small rim of peripheral tissue to contain the implant.⁹ The device currently targets the medial compartment only, so lateral meniscus deficiency is not addressed by it.

One practical reality that shapes candidacy is that many patients who receive a meniscal scaffold also undergo simultaneous procedures. In the systematic reviews, nearly half of Actifit and CMI patients had concurrent surgeries like ligament reconstruction or osteotomy to correct leg alignment.⁴ That makes it harder to isolate the scaffold’s contribution to outcome improvement, and it means the decision to implant a scaffold is often part of a larger surgical strategy rather than a standalone choice.

The Cost Question

A meniscal replacement device adds cost to a procedure compared to doing nothing after meniscectomy, and it is fair to ask whether the expense is justified. A cost-effectiveness analysis conducted for the United Kingdom’s healthcare system looked at the NUsurface prosthesis and found that the incremental cost per quality-adjusted life year gained was about £5,000, well below the National Institute for Health and Care Excellence threshold of £20,000 that is typically used to judge whether an intervention represents reasonable value.¹⁵ Per-patient costs increased by roughly £6,600, but patients gained an estimated 1.3 quality-adjusted life years. The analysis hinges on the assumption that the device delays or avoids the need for a total knee replacement, which is far more expensive and limits function more permanently. If the device fails early and a knee replacement is still needed, the economic argument weakens.

3D Bioprinting and the Next Generation

The scaffolds and prosthetics available today are essentially off-the-shelf devices fitted to the patient at surgery. The next frontier is custom-building a meniscus from living cells. Several research groups have made progress in bioprinting meniscal tissue using inks composed of collagen, chondroitin sulfate, and mesenchymal stem cells.

Lab studies have shown that bioprinted menisci containing live cells can withstand repeated compression cycles over weeks without cell death, and the cells under compression actually contributed to strengthening the construct rather than weakening it.¹⁶ That finding is encouraging because the meniscus in a real knee is under near-constant compressive load, so any replacement tissue must tolerate that environment.

Researchers have also bioprinted full human-sized meniscus shapes seeded with adipose-derived mesenchymal stem cells differentiated toward a cartilage-producing lineage. These constructs achieved about 97% cell viability after printing and showed extracellular matrix formation, though they are nowhere near the mechanical strength of a real meniscus yet.¹⁷ One experiment even printed meniscal tissue aboard the International Space Station, where the microgravity environment allowed assessment of how well the tissue maintained shape fidelity without the confounding effect of gravity pulling on the soft construct during fabrication. The space-printed tissue matched Earth-printed controls in dimensions and showed good cell distribution throughout.¹⁸

Bioprinted menisci are years away from clinical use. The gap between a living construct that survives in a bioreactor for three weeks and one that can handle the repeated forces of walking, running, and pivoting in a human knee for a decade is enormous. Still, the trajectory is clear: the goal is to eventually create a patient-specific, cell-seeded replacement that integrates with the body the way native tissue would, rather than relying on a synthetic device that the body merely tolerates.

What the Field Still Gets Wrong About Meniscal Replacement

The biggest misconception patients encounter is that meniscal replacement devices work like joint replacements. A hip or knee replacement is a mature, standardized technology with decades of survival data and predictable outcomes. Meniscal replacement is not there yet. Reoperation rates are high, especially for the NUsurface, and the “best” option varies significantly depending on how much meniscal tissue remains, which compartment of the knee is affected, and what concurrent procedures are needed. Calling these devices “replacements” may set expectations the technology cannot yet consistently meet; “meniscal restoration” or “meniscal supplementation” would be more accurate for the scaffolds, at least.

A second misconception is that synthetic devices are always better than donor tissue. The data showing synthetic scaffolds outperform allografts on certain scores is real, but the two approaches serve different populations. An allograft is sometimes the only option, and it remains the workhorse of total meniscal reconstruction when no native rim tissue is left. Writing off allografts because a meta-analysis favored synthetics on averaged outcome scores misses the clinical reality.

Finally, there is a tendency to talk about meniscal replacement as if it is a single technology. In practice, the field includes devices with fundamentally different strategies: biodegradable scaffolds that vanish as your body fills them in, permanent prosthetics that stay in the knee for life, transplanted donor tissue that remodels over time, and experimental bioprinted constructs that are part scaffold and part living tissue. Each has different risks, different indications, and different recovery demands. Asking “should I get an artificial meniscus?” is a bit like asking “should I get surgery?”—the answer depends entirely on which procedure is being discussed and what your knee actually needs.